| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 128 | 2025 | 2763 | 10.930 |
Why?
|
| Receptor, ErbB-2 | 54 | 2025 | 559 | 7.750 |
Why?
|
| Drug Resistance, Neoplasm | 62 | 2025 | 821 | 7.400 |
Why?
|
| Receptors, Estrogen | 57 | 2024 | 828 | 6.430 |
Why?
|
| Antineoplastic Agents, Hormonal | 38 | 2022 | 271 | 4.420 |
Why?
|
| Estrogen Receptor alpha | 21 | 2022 | 474 | 3.400 |
Why?
|
| Tamoxifen | 35 | 2022 | 377 | 3.360 |
Why?
|
| Trastuzumab | 26 | 2025 | 154 | 2.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2025 | 1353 | 2.390 |
Why?
|
| Quinazolines | 20 | 2023 | 184 | 2.270 |
Why?
|
| Signal Transduction | 55 | 2025 | 4899 | 1.920 |
Why?
|
| Antineoplastic Agents | 24 | 2022 | 1851 | 1.850 |
Why?
|
| Gene Expression Regulation, Neoplastic | 39 | 2024 | 2122 | 1.630 |
Why?
|
| Cell Line, Tumor | 56 | 2025 | 3752 | 1.440 |
Why?
|
| ErbB Receptors | 15 | 2020 | 303 | 1.360 |
Why?
|
| Xenograft Model Antitumor Assays | 26 | 2024 | 1006 | 1.290 |
Why?
|
| Receptor Cross-Talk | 11 | 2015 | 37 | 1.280 |
Why?
|
| Mice, Nude | 32 | 2025 | 777 | 1.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 10 | 2019 | 351 | 1.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2024 | 67 | 1.190 |
Why?
|
| Molecular Targeted Therapy | 10 | 2025 | 407 | 1.190 |
Why?
|
| Neoadjuvant Therapy | 12 | 2023 | 404 | 1.110 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2024 | 50 | 1.100 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 4 | 2022 | 49 | 1.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 6 | 2018 | 101 | 1.070 |
Why?
|
| Estradiol | 11 | 2022 | 552 | 1.060 |
Why?
|
| Transcription Factor AP-1 | 5 | 2022 | 111 | 1.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2023 | 82 | 1.030 |
Why?
|
| Genes, erbB-2 | 6 | 2013 | 38 | 1.020 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2017 | 262 | 0.990 |
Why?
|
| Estrogen Receptor Modulators | 8 | 2008 | 39 | 0.970 |
Why?
|
| Female | 116 | 2025 | 71722 | 0.940 |
Why?
|
| Biomarkers, Tumor | 17 | 2024 | 1720 | 0.900 |
Why?
|
| Cell Proliferation | 27 | 2024 | 2548 | 0.860 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2025 | 132 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2025 | 611 | 0.820 |
Why?
|
| Pyridines | 3 | 2024 | 247 | 0.810 |
Why?
|
| Mice | 58 | 2025 | 18915 | 0.810 |
Why?
|
| Piperazines | 3 | 2024 | 257 | 0.800 |
Why?
|
| Humans | 143 | 2025 | 134000 | 0.800 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 137 | 0.780 |
Why?
|
| Estrogens | 12 | 2022 | 522 | 0.780 |
Why?
|
| Apoptosis | 16 | 2024 | 1930 | 0.740 |
Why?
|
| MCF-7 Cells | 12 | 2021 | 232 | 0.740 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2020 | 556 | 0.710 |
Why?
|
| Animals | 66 | 2025 | 36401 | 0.710 |
Why?
|
| Gene Expression Profiling | 12 | 2021 | 1919 | 0.700 |
Why?
|
| Interferons | 1 | 2022 | 146 | 0.690 |
Why?
|
| Prognosis | 22 | 2025 | 5082 | 0.680 |
Why?
|
| Aromatase Inhibitors | 6 | 2017 | 79 | 0.680 |
Why?
|
| Precision Medicine | 2 | 2019 | 355 | 0.630 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 11 | 2013 | 1069 | 0.610 |
Why?
|
| Circulating Tumor DNA | 1 | 2018 | 40 | 0.580 |
Why?
|
| Lymphocytes | 1 | 2019 | 440 | 0.560 |
Why?
|
| Indoles | 1 | 2018 | 201 | 0.560 |
Why?
|
| Gene Amplification | 6 | 2019 | 247 | 0.550 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 318 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2024 | 217 | 0.530 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 78 | 0.520 |
Why?
|
| Receptors, Growth Factor | 3 | 2005 | 37 | 0.510 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2025 | 315 | 0.500 |
Why?
|
| Interleukin-8 | 1 | 2016 | 221 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 352 | 0.480 |
Why?
|
| RNA, Small Interfering | 13 | 2018 | 714 | 0.480 |
Why?
|
| Chromatin | 4 | 2022 | 609 | 0.460 |
Why?
|
| Tumor Cells, Cultured | 12 | 2021 | 1102 | 0.450 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 690 | 0.450 |
Why?
|
| Epidermal Growth Factor | 5 | 2021 | 125 | 0.440 |
Why?
|
| Growth Substances | 4 | 2004 | 115 | 0.430 |
Why?
|
| Transcriptome | 4 | 2016 | 1136 | 0.410 |
Why?
|
| Estrogen Antagonists | 4 | 2022 | 106 | 0.400 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2014 | 246 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 183 | 0.390 |
Why?
|
| Up-Regulation | 8 | 2016 | 905 | 0.390 |
Why?
|
| Mucin-4 | 1 | 2012 | 11 | 0.390 |
Why?
|
| Sirolimus | 1 | 2014 | 253 | 0.390 |
Why?
|
| Receptors, Progesterone | 5 | 2015 | 897 | 0.370 |
Why?
|
| Integrin beta1 | 1 | 2011 | 56 | 0.370 |
Why?
|
| Phosphorylation | 12 | 2021 | 1701 | 0.370 |
Why?
|
| Transcription, Genetic | 8 | 2020 | 1757 | 0.360 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 91 | 0.360 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 168 | 0.360 |
Why?
|
| Oncogene Proteins | 3 | 2021 | 151 | 0.360 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2018 | 142 | 0.350 |
Why?
|
| Gene Expression | 6 | 2020 | 1614 | 0.320 |
Why?
|
| Mutation | 12 | 2019 | 6298 | 0.310 |
Why?
|
| Carcinoma | 2 | 2015 | 322 | 0.310 |
Why?
|
| Protein Kinases | 4 | 2016 | 343 | 0.310 |
Why?
|
| Adaptation, Physiological | 2 | 2021 | 291 | 0.300 |
Why?
|
| Gold | 3 | 2014 | 57 | 0.300 |
Why?
|
| Estrogen Receptor beta | 3 | 2008 | 87 | 0.300 |
Why?
|
| Cell Cycle | 6 | 2024 | 626 | 0.300 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2018 | 267 | 0.290 |
Why?
|
| Transplantation, Heterologous | 8 | 2011 | 275 | 0.290 |
Why?
|
| Proteome | 1 | 2010 | 281 | 0.290 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2020 | 456 | 0.290 |
Why?
|
| Epigenesis, Genetic | 4 | 2019 | 773 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2017 | 508 | 0.290 |
Why?
|
| Fibroblasts | 5 | 2022 | 925 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2014 | 212 | 0.280 |
Why?
|
| Dyslexia | 2 | 2019 | 30 | 0.280 |
Why?
|
| Carcinogenesis | 4 | 2025 | 363 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 401 | 0.270 |
Why?
|
| Neoplasm Transplantation | 9 | 2019 | 399 | 0.270 |
Why?
|
| Transcription Factors | 5 | 2019 | 2704 | 0.260 |
Why?
|
| Histone Acetyltransferases | 4 | 2020 | 317 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2014 | 644 | 0.260 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2016 | 1070 | 0.250 |
Why?
|
| Cellular Reprogramming | 2 | 2020 | 135 | 0.250 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 1386 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 6 | 2018 | 395 | 0.240 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 10 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2018 | 19 | 0.240 |
Why?
|
| Survival Analysis | 4 | 2020 | 1596 | 0.230 |
Why?
|
| RNA Interference | 5 | 2019 | 544 | 0.230 |
Why?
|
| Nanoshells | 3 | 2014 | 13 | 0.230 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 718 | 0.220 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1606 | 0.220 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 161 | 0.220 |
Why?
|
| Enzyme Inhibitors | 4 | 2020 | 607 | 0.220 |
Why?
|
| Heterografts | 3 | 2022 | 199 | 0.220 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2024 | 90 | 0.220 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 584 | 0.210 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 24 | 0.210 |
Why?
|
| Blotting, Western | 7 | 2011 | 1134 | 0.210 |
Why?
|
| Carrier Proteins | 3 | 2020 | 1066 | 0.210 |
Why?
|
| Repressor Proteins | 4 | 2014 | 869 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2014 | 295 | 0.200 |
Why?
|
| Carcinoma, Lobular | 1 | 2022 | 26 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2018 | 264 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 747 | 0.200 |
Why?
|
| GATA3 Transcription Factor | 2 | 2020 | 39 | 0.190 |
Why?
|
| Clonal Evolution | 2 | 2021 | 49 | 0.190 |
Why?
|
| Phototherapy | 2 | 2014 | 39 | 0.190 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 8 | 0.190 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 7 | 0.190 |
Why?
|
| Drug Synergism | 2 | 2016 | 239 | 0.190 |
Why?
|
| Treatment Outcome | 14 | 2025 | 13014 | 0.190 |
Why?
|
| Remission Induction | 2 | 2020 | 308 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2021 | 68 | 0.180 |
Why?
|
| Middle Aged | 16 | 2025 | 29432 | 0.180 |
Why?
|
| F-Box Proteins | 2 | 2019 | 37 | 0.180 |
Why?
|
| src-Family Kinases | 4 | 2020 | 97 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 5 | 2019 | 1418 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5511 | 0.180 |
Why?
|
| Attention | 2 | 2019 | 208 | 0.170 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2022 | 62 | 0.170 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2020 | 51 | 0.170 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 45 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 616 | 0.160 |
Why?
|
| Nuclear Proteins | 4 | 2020 | 1334 | 0.160 |
Why?
|
| Thiophenes | 1 | 2020 | 72 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 791 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 21 | 0.160 |
Why?
|
| Auditory Perception | 1 | 2019 | 41 | 0.160 |
Why?
|
| Cell Survival | 6 | 2021 | 889 | 0.160 |
Why?
|
| Keratins | 2 | 2019 | 52 | 0.160 |
Why?
|
| Aged | 14 | 2025 | 21754 | 0.160 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 63 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2022 | 482 | 0.160 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 357 | 0.150 |
Why?
|
| Phenotype | 9 | 2016 | 4551 | 0.150 |
Why?
|
| Integrin alpha6 | 1 | 2018 | 6 | 0.150 |
Why?
|
| Trans-Activators | 1 | 2003 | 830 | 0.150 |
Why?
|
| Executive Function | 1 | 2019 | 125 | 0.150 |
Why?
|
| Dendritic Cells | 1 | 2022 | 448 | 0.150 |
Why?
|
| Visual Perception | 1 | 2019 | 135 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2021 | 310 | 0.150 |
Why?
|
| Proteogenomics | 1 | 2020 | 102 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 233 | 0.150 |
Why?
|
| Mice, SCID | 3 | 2019 | 613 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2024 | 232 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 36 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 757 | 0.140 |
Why?
|
| Adult | 15 | 2025 | 31983 | 0.140 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 66 | 0.140 |
Why?
|
| Flavonoids | 1 | 2018 | 87 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2010 | 2902 | 0.140 |
Why?
|
| Lasers | 2 | 2014 | 118 | 0.140 |
Why?
|
| Proteomics | 2 | 2013 | 595 | 0.130 |
Why?
|
| Protein Binding | 5 | 2020 | 1832 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2017 | 87 | 0.130 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 4780 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 497 | 0.120 |
Why?
|
| Cytokines | 1 | 2022 | 1396 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2000 | 871 | 0.120 |
Why?
|
| Chlorophyll | 1 | 2014 | 5 | 0.120 |
Why?
|
| Receptor, ErbB-4 | 1 | 2015 | 9 | 0.120 |
Why?
|
| Tumor Burden | 2 | 2014 | 257 | 0.120 |
Why?
|
| Drug Liberation | 1 | 2014 | 37 | 0.120 |
Why?
|
| Mice, Inbred NOD | 2 | 2013 | 318 | 0.120 |
Why?
|
| Reading | 1 | 2015 | 84 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1761 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 244 | 0.110 |
Why?
|
| Photochemistry | 1 | 2014 | 23 | 0.110 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 13 | 0.110 |
Why?
|
| Genes, myc | 2 | 2011 | 107 | 0.110 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 243 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2014 | 52 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 1079 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 59 | 0.110 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2005 | 141 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2022 | 2025 | 0.110 |
Why?
|
| Language | 1 | 2015 | 219 | 0.110 |
Why?
|
| Phosphatidylinositols | 1 | 2013 | 32 | 0.110 |
Why?
|
| Doxycycline | 1 | 2014 | 121 | 0.110 |
Why?
|
| Liposomes | 1 | 2014 | 207 | 0.110 |
Why?
|
| Glutarates | 1 | 2013 | 38 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 59 | 0.110 |
Why?
|
| Down-Regulation | 5 | 2021 | 717 | 0.110 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 4 | 0.110 |
Why?
|
| Cell Membrane | 2 | 2013 | 486 | 0.100 |
Why?
|
| Nuclear Receptor Coactivator 3 | 3 | 2010 | 351 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 838 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2013 | 32 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 59 | 0.100 |
Why?
|
| Random Allocation | 1 | 2014 | 450 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 175 | 0.100 |
Why?
|
| Cytoplasm | 2 | 2011 | 302 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 202 | 0.100 |
Why?
|
| Neoplasms | 3 | 2014 | 3027 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 510 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 332 | 0.100 |
Why?
|
| CD24 Antigen | 1 | 2012 | 32 | 0.100 |
Why?
|
| Mammary Glands, Human | 2 | 2010 | 83 | 0.100 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 68 | 0.100 |
Why?
|
| Genomics | 1 | 2020 | 1675 | 0.090 |
Why?
|
| Models, Biological | 3 | 2008 | 1532 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2025 | 1139 | 0.090 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2011 | 23 | 0.090 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2012 | 143 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 97 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 454 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 1788 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 115 | 0.090 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2010 | 32 | 0.090 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 352 | 0.090 |
Why?
|
| Lentivirus | 1 | 2011 | 86 | 0.090 |
Why?
|
| Ovariectomy | 2 | 2008 | 188 | 0.090 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2010 | 47 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2010 | 32 | 0.090 |
Why?
|
| Genetic Techniques | 1 | 2011 | 109 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2008 | 95 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 317 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1326 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 708 | 0.080 |
Why?
|
| Cell Division | 3 | 2007 | 774 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2011 | 382 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 382 | 0.080 |
Why?
|
| Immunoconjugates | 1 | 2010 | 45 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 178 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 271 | 0.080 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Triazoles | 3 | 2015 | 142 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2008 | 11 | 0.080 |
Why?
|
| Gene Silencing | 3 | 2016 | 247 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 7215 | 0.080 |
Why?
|
| Mesoderm | 1 | 2008 | 113 | 0.070 |
Why?
|
| Transfection | 4 | 2013 | 1089 | 0.070 |
Why?
|
| Endocrine System | 1 | 2008 | 22 | 0.070 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2008 | 15 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 3057 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 370 | 0.070 |
Why?
|
| Indium Radioisotopes | 1 | 2007 | 9 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 284 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2010 | 676 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2010 | 252 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2007 | 112 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2011 | 970 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 171 | 0.070 |
Why?
|
| Receptors, Somatotropin | 1 | 2006 | 9 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2008 | 456 | 0.060 |
Why?
|
| Cell Separation | 2 | 2019 | 234 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 254 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1316 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 83 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1154 | 0.060 |
Why?
|
| Polyamines | 1 | 2005 | 29 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2006 | 78 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 589 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 971 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 71 | 0.060 |
Why?
|
| Cell Cycle Proteins | 3 | 2014 | 697 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 129 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2005 | 151 | 0.060 |
Why?
|
| Silicon Dioxide | 2 | 2014 | 31 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 94 | 0.050 |
Why?
|
| DNA Methylation | 3 | 2017 | 1143 | 0.050 |
Why?
|
| Particle Size | 2 | 2014 | 148 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 463 | 0.050 |
Why?
|
| Forecasting | 1 | 2005 | 377 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1871 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 1484 | 0.050 |
Why?
|
| Nitriles | 2 | 2015 | 155 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 98 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 159 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2003 | 91 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2003 | 244 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 143 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 668 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 252 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 29 | 0.050 |
Why?
|
| Cadherins | 1 | 2003 | 186 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 3478 | 0.050 |
Why?
|
| Computational Biology | 2 | 2020 | 887 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2021 | 26 | 0.050 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 18 | 0.050 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 62 | 0.050 |
Why?
|
| Metabolome | 2 | 2014 | 312 | 0.050 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 62 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1735 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 292 | 0.040 |
Why?
|
| Gap Junctions | 1 | 2021 | 45 | 0.040 |
Why?
|
| G1 Phase | 1 | 2021 | 67 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 80 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2000 | 37 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 44 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2020 | 55 | 0.040 |
Why?
|
| Cell Line | 3 | 2011 | 2836 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 99 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 50 | 0.040 |
Why?
|
| Cell Movement | 2 | 2014 | 916 | 0.040 |
Why?
|
| Cell Communication | 1 | 2021 | 186 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 453 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 163 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2020 | 110 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2021 | 395 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 167 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 187 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 34 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 836 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 77 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 401 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 183 | 0.040 |
Why?
|
| Cyclopentanes | 1 | 2019 | 22 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 127 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 98 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 433 | 0.040 |
Why?
|
| Protein Isoforms | 3 | 2008 | 429 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 318 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2010 | 644 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 93 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2014 | 941 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 183 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 172 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 611 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2020 | 182 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2010 | 2526 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3981 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 498 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 755 | 0.040 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.040 |
Why?
|
| Time Factors | 3 | 2015 | 6591 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 2295 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2018 | 136 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 619 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 572 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 149 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2011 | 324 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2010 | 371 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 447 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2019 | 417 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 688 | 0.030 |
Why?
|
| Linguistics | 1 | 2015 | 20 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 218 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 248 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2011 | 472 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 1132 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 168 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1486 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 9902 | 0.030 |
Why?
|
| Fluoresceins | 1 | 2014 | 36 | 0.030 |
Why?
|
| Bias | 1 | 2015 | 147 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 61 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 317 | 0.030 |
Why?
|
| Lasers, Semiconductor | 1 | 2014 | 9 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2015 | 235 | 0.030 |
Why?
|
| Transducers | 1 | 2014 | 26 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2014 | 25 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 119 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 2014 | 50 | 0.030 |
Why?
|
| Surface Properties | 1 | 2014 | 95 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 254 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2210 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 80 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 25 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 400 | 0.030 |
Why?
|
| Light | 1 | 2014 | 187 | 0.030 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2013 | 22 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 70 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 65 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 220 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 144 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 193 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 120 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 141 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 2 | 2003 | 23 | 0.030 |
Why?
|
| Disease Progression | 2 | 2013 | 2243 | 0.030 |
Why?
|
| fas Receptor | 1 | 2013 | 50 | 0.030 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 2 | 2003 | 55 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 195 | 0.030 |
Why?
|
| Optics and Photonics | 1 | 2014 | 143 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 547 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 83 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1833 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 371 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 991 | 0.020 |
Why?
|
| Plasmids | 1 | 2013 | 527 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 222 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 300 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 206 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2011 | 50 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 39 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 428 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 260 | 0.020 |
Why?
|
| Luminescence | 1 | 2011 | 18 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 621 | 0.020 |
Why?
|
| Foreskin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 194 | 0.020 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 28 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Polyribosomes | 1 | 2010 | 26 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 96 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 290 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 72 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 103 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 801 | 0.020 |
Why?
|
| Sphingosine | 1 | 2010 | 17 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 240 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 456 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2010 | 33 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 93 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 31 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 568 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 79 | 0.020 |
Why?
|
| p21-Activated Kinases | 1 | 2010 | 58 | 0.020 |
Why?
|
| Ribosomes | 1 | 2010 | 139 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2010 | 152 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2009 | 9 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 610 | 0.020 |
Why?
|
| Dideoxynucleosides | 1 | 2009 | 10 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1350 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 251 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1736 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 201 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 47 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 37 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2008 | 20 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 136 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2013 | 6664 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1489 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2008 | 123 | 0.020 |
Why?
|
| Mitochondria | 1 | 2013 | 746 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3644 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 282 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 388 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 230 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 225 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 477 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 310 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 106 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1908 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 279 | 0.020 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Dendrimers | 1 | 2005 | 6 | 0.020 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2005 | 12 | 0.020 |
Why?
|
| Rhodamines | 1 | 2005 | 22 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 194 | 0.020 |
Why?
|
| Mitogens | 1 | 2005 | 32 | 0.020 |
Why?
|
| Acetophenones | 1 | 2005 | 13 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2005 | 21 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2005 | 17 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 3432 | 0.010 |
Why?
|
| Wnt1 Protein | 1 | 2005 | 73 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 300 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 109 | 0.010 |
Why?
|
| Glucose | 1 | 2009 | 924 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2005 | 234 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 250 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2005 | 223 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 337 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2011 | 951 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 169 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 570 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2989 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 206 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 526 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 254 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 407 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1337 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 1417 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 1304 | 0.010 |
Why?
|
| Male | 2 | 2019 | 65941 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2196 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 1674 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3852 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1999 | 263 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 2656 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 17497 | 0.010 |
Why?
|